Digitoxin

Digitoxin

Clinical data
ATC code	C01AA04 (WHO)
Identifiers
IUPAC name 5β,20(22)-Cardenolide-3β,14-diol-3- (O-2,6-dideoxy-β-D-ribo-hexopyranosyl- [1→4]-O-2,6-dideoxy-β-D-ribo-hexopyranosyl- [1→4]-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy
CAS Number	71-63-6
PubChem CID	3061
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C41H64O13
Molar mass	764.939 g/mol

WikiDoc Resources for Digitoxin
Articles
Most recent articles on Digitoxin Most cited articles on Digitoxin Review articles on Digitoxin Articles on Digitoxin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Digitoxin Images of Digitoxin Photos of Digitoxin Podcasts & MP3s on Digitoxin Videos on Digitoxin
Evidence Based Medicine
Cochrane Collaboration on Digitoxin Bandolier on Digitoxin TRIP on Digitoxin
Clinical Trials
Ongoing Trials on Digitoxin at Clinical Trials.gov Trial results on Digitoxin Clinical Trials on Digitoxin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Digitoxin NICE Guidance on Digitoxin NHS PRODIGY Guidance FDA on Digitoxin CDC on Digitoxin
Books
Books on Digitoxin
News
Digitoxin in the news Be alerted to news on Digitoxin News trends on Digitoxin
Commentary
Blogs on Digitoxin
Definitions
Definitions of Digitoxin
Patient Resources / Community
Patient resources on Digitoxin Discussion groups on Digitoxin Patient Handouts on Digitoxin Directions to Hospitals Treating Digitoxin Risk calculators and risk factors for Digitoxin
Healthcare Provider Resources
Symptoms of Digitoxin Causes & Risk Factors for Digitoxin Diagnostic studies for Digitoxin Treatment of Digitoxin
Continuing Medical Education (CME)
CME Programs on Digitoxin
International
Digitoxin en Espanol Digitoxin en Francais
Business
Digitoxin in the Marketplace Patents on Digitoxin
Experimental / Informatics
List of terms related to Digitoxin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Digitoxin is a cardiac glycoside. It has similar structure and effects to digoxin (though the effects are longer-lasting). Unlike digoxin (which is eliminated from the body via the kidneys), it is eliminated via the liver, so could be used in patients with poor or erratic kidney function. However, it is now rarely used in current UK medical practice. While there have been several controlled trials which have shown digoxin to be effective in a proportion of patients treated for heart failure, there is not the same strong evidence base for digitoxin, although it is presumed to be similarly effective.

Toxicity

Digitoxin exhibits similar toxic effects to the more-commonly used digoxin, namely: anorexia, nausea, vomiting, diarrhoea, confusion, visual disturbances, and cardiac arrhythmias. Anti-digoxin antibody fragments, the specific treatment for digoxin poisoning, are also effective in serious digitoxin toxicity.

External links

• "Comparing the Toxicity of Digoxin and Digitoxin in a Geriatric Population: Should an Old Drug Be Rediscovered?"
• Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claeson P (2001). "Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells". Anticancer Drugs. 12 (5): 475–83. PMID 11395576.CS1 maint: Multiple names: authors list (link)
• Hippius M, Humaid B, Sicker T, Hoffmann A, Göttler M, Hasford J (2001). "Adverse drug reaction monitoring--digitoxin overdosage in the elderly". Int J Clin Pharmacol Ther. 39 (8): 336–43. PMID 11515708.CS1 maint: Multiple names: authors list (link)
• Belz G, Breithaupt-Grögler K, Osowski U. "Treatment of congestive heart failure--current status of use of digitoxin". Eur J Clin Invest. 31 Suppl 2: 10–7. PMID 11525233.CS1 maint: Multiple names: authors list (link)
• Haux J, Klepp O, Spigset O, Tretli S. "Digitoxin medication and cancer; case control and internal dose-response studies". BMC Cancer. 1: 11. PMID 11532201.CS1 maint: Multiple names: authors list (link)
• Srivastava M, Eidelman O, Zhang J, Paweletz C, Caohuy H, Yang Q, Jacobson K, Heldman E, Huang W, Jozwik C, Pollard B, Pollard H (2004). "Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells". Proc Natl Acad Sci U S A. 101 (20): 7693–8. PMID 15136726.CS1 maint: Multiple names: authors list (link)

http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/D5878

Template:WikiDoc Sources